Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.57 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.46 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | CA7 | P43166 | 7/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | CA4 | P22748 | 6/20 | 0.42 |
| ▸ | CA6 | P23280 | 6/20 | 0.42 |
| ▸ | CA5A | P35218 | 6/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12527297 | 0.82 | ABCC9 (0.49) | HSD11B1KIF18AABCC9ABCC8KCNJ11 | |
| SCHEMBL2462163 | 0.81 | KIF18A (0.61) | HSD11B1KIF18AABCC9ABCC8KCNJ11 | |
| SCHEMBL16663 | 0.79 | RXFP1 (0.42) | HSD11B1KIF18AABCC9ABCC8KCNJ11 | |
| SCHEMBL10973897 | 0.79 | AKR1B1 (0.50) | HSD11B1KIF18AABCC9ABCC8KCNJ11 | |
| SCHEMBL8866123 | 0.79 | HSD11B1 (0.57) | HSD11B1KIF18AABCC9ABCC8KCNJ11 | |
| SCHEMBL2350373 | 0.79 | AKR1B1 (0.51) | HSD11B1KIF18AABCC9ABCC8KCNJ11 | |
| SCHEMBL226516 | 0.78 | HTR6 (0.48) | HTR6POLBGAAGFERCA1 | |
| SCHEMBL9475086 | 0.78 | HSD11B1 (0.64) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL229081 | 0.78 | HTR6 (0.48) | KIF18AHTR6POLBGAAGFER | |
| SCHEMBL9756875 | 0.77 | HSD11B1 (0.50) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| CN-101326160-B | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB | 2013-04-17 | — | — | CN | disclosed |
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8349897-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2013-01-08 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-1937633-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| CN-101326160-A | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2008-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | HSD11B1 1023/4885KIF18A 1846/4885ABCC9 1711/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | HSD11B1 1443/4885KIF18A 3337/4885ABCC9 862/4885 |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | HSD11B1 1023/4885KIF18A 1846/4885ABCC9 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.